Informations sur le nombre total de droits de vote et d'actions

Nyxoah SA disclosed issuance of 146,531 new shares on 30 Jun 2026 from the exercise of Restricted Share Units, bringing total capital to €7,075,152.31 and total voting rights to 100,072,815. The company also reported 225 convertible bonds (nominal €83,000 each) with a current conversion price of €1.48 per share, implying potential additional voting rights of 12,618,243 on conversion.

Analysis

The only investable signal here is not the share issuance itself, but the continuing expansion of the fully diluted capital structure. In a small-cap medtech, incremental RSUs are usually immaterial for day-to-day pricing, but they matter because they tell you the company is still compensating with equity rather than proving operating leverage; that tends to keep per-share models under pressure and caps multiple expansion until cash generation is visible.

The bigger overhang is the convert stack: if the share price ever gets close enough for those instruments to matter, the market will already be debating whether the business is self-funding or simply refinancing dilution with dilution. That creates a classic ceiling on upside in the next 1-3 months: any rally driven by sentiment can be met by supply from holders monetizing into strength, while the cleanest fundamental catalyst would be a quarterly update showing burn reduction and a longer runway.

Contrarian view: the headline dilution risk is likely overstated for today because the incremental shares are de minimis versus the current float. The real issue is 6-18 months out—whether commercial traction is strong enough to prevent another capital raise, which would be the event that actually compresses the equity value of each future sale. On the other side, if execution improves, the stock can re-rate sharply because small-cap medtechs are valued on perceived survival probability, not current earnings.

Key Decisions for Investors

• No immediate trade on the RSU issuance alone; treat any dip on this filing as noise unless NYXH falls more than 5% on sustained volume, which would suggest the market is pricing in broader financing risk.
• Relative-value idea: long INSP / short NYXH over 3-6 months if you want OSA exposure with a cleaner per-share path; this works best if NYXH continues to rely on equity compensation and the market starts discounting future dilution.
• Set a watch item on the next quarterly cash-burn and runway disclosure; if runway compresses below 12 months or management softens commercial guidance, expect another financing overhang and a likely 15-25% multiple reset.
• If NYXH rallies back toward financing optimism without a corresponding improvement in operating metrics, fade strength rather than chase it; the risk/reward on the short side improves when valuation is being driven by sentiment instead of self-funding evidence.